Mata Velasco, E., González-Flores, E., Juez Martel, I., Alonso, V., Iranzo Gomez, P., Martinez Lago, N., Lopez, C., Cabrera Romero, J. M., Safont Aguilera, M. J., Ruiz Casado, A., Salgado Fernandez, M., González Astorga, B., Escudero, P., Rivera Herrero, F., Pericay Pijaume, C., & Vera, R. (n.d.). 478PIn the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR?. Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095476312.0x000039